Exenatide

Exenatide (exendin-4–based GLP-1 receptor agonist)

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

An exendin-4–based GLP-1 receptor agonist used in approved prescription products for labeled uses. In EXSCEL, once-weekly exenatide established cardiovascular safety noninferiority, not cardiovascular superiority.

Plain English

Researchers study Exenatide as an exendin-4–based GLP-1 receptor agonist. Its approved uses, safety information, and dosing are specific to the applicable product, formulation, and label. The EXSCEL trial tested once-weekly exenatide in a defined population and established cardiovascular safety noninferiority; it did not demonstrate cardiovascular superiority.

Overview

Exenatide is an exendin-4–based GLP-1 receptor agonist used in immediate-release and extended-release prescription formulations. Evidence and regulatory conclusions are formulation- and indication-specific; results for once-weekly exenatide should not be generalized to other GLP-1 receptor agonists.

Research Summary

In the EXSCEL randomized cardiovascular-outcomes trial, once-weekly exenatide met the prespecified noninferiority criterion for major cardiovascular events versus placebo but did not demonstrate superiority. This result is specific to the studied formulation and population.

Research Areas

  • Type 2 diabetes
  • GLP-1 receptor pharmacology
  • Weight management
  • Cardiovascular outcomes in type 2 diabetes

Safety & Risks

Serious Risks

  • Acute pancreatitis; discontinue and evaluate if suspected.
  • Renal-use limitations may apply to the specific product and patient context.
  • Hypoglycemia risk when used with relevant concomitant therapies.

Reported Side Effects

  • Nausea (very common at initiation, decreases over time)
  • Vomiting
  • Diarrhea
  • Headache
  • Injection site nodules (ER form — microsphere depot reaction)
United States
Product-, formulation-, indication-, and label-specific; consult the current official source.
United Kingdom
Product-, formulation-, indication-, and label-specific; consult the current official source.
Australia
Product-, formulation-, indication-, and label-specific; consult the current official source.
Canada
Product-, formulation-, indication-, and label-specific; consult the current official source.

Citations & Sources